

Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026

<https://marketpublishers.com/r/G055DA2F285AEN.html>

Date: May 2020

Pages: 510

Price: US\$ 3,000.00 (Single User License)

ID: G055DA2F285AEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026' Report Highlights:

Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs

Marketed Cancer Antibody Drug Conjugate: 9 Drugs

Antibody Drug Conjugate Marketed Opportunity: > US\$ 13 Billion By 2026

Majority of Drug Trials Are For Second Line Therapy Or Greater

USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs

Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs

Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs

'Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026' offers comprehensive clinical and non clinical insight on the recent trends and the opportunities that the market has been experiencing at a regional and at global level. The cancer antibody drug conjugate market has been witnessing tremendous growth and offers unexplored potential to pharmaceutical companies involved in development of anti cancer therapeutics market. This new drug class is widely accepted in the form of

monotherapy as well as combinational therapy among the Breast Cancer, Acute Leukemia and Lymphoma patients. In addition to the various strategies that have been employed by the major key players of the market, the report also delivers information regarding the achievements, valuable highlights and all the progressive compilations that have been made in the market.

After the approval of first ADC i.e. Pfizer's Mylotarg in year 2000, the antibody drug conjugates are continuously witnessing exponential growth and are emerging as most prominent therapeutic approach for the management of cancer. After the withdrawal of Mylotarg, two new antibody drug conjugates entered into the market, which took the market to the next level. Further, the Mylotarg was also reintroduced into the market in 2017 and currently 9 cancer antibody drug conjugates are available in the market, which are continuously boosting the drug conjugates market.

The drugs launched under antibody drug conjugates class have been designed in a way such that they show promising targeting activity. The drugs incorporate antibody specificity as well as cell killing activity of cytotoxic agents that have been chemically conjugated. Other than the efficient targeting activity, the drugs under it have been prominent in showing various other clinical applications. With 9 antibody drug conjugates available in the market and all being tremendously successful, namely Lumoxiti, Polivy, Mylotarg, Besponsa, Kadcyla and Adcetris, this therapeutic method have been classified as a potent treatment in oncology.

An advantage that is associated with this class of therapeutics is that it has the ability to effectively identify the cells that are foreign or not healthy. In the present scenario, all the clinicians, non-clinicians and the patients are getting inclined towards it as it has overcome the challenge that were highlighted during other treatment procedure i.e. toxicity related issues. The current trend that the market states is that this novel therapeutic regimen has now become a part of mainstream oncology healthcare system and has achieved significant warmth in the oncology department all around the globe.

As per report findings, the cancer antibody drug conjugates will shown tremendous success in the upcoming years in both the research and market segments. The continuous success of the approved cancer antibody drug conjugates and presence of many new antibody drug conjugates in the clinical pipeline is indicating a very bright future for this market. The challenges for this market are very few, which can be easily prevail over in a short period of time and the driving factors such as unmet medical demand and high prevalence of cancer, are continuously boosting the market growth. We believe that in upcoming years, the antibody drug conjugates will occupy a

dominant share in overall oncology market and it will emerge as most prominent cancer therapeutic segment.

Contents

1. INTRODUCTION TO ANTIBODY DRUG CONJUGATES (ADCs)

- 1.1 Overview
- 1.2 Historical Development of ADCs

2. EVOLUTION OF ANTIBODY DRUG CONJUGATES

- 2.1 Advancements in ADCs
 - 2.1.1 First Generation
 - 2.1.2 Second-Generation
 - 2.1.3 Third Generation
- 2.2 Components of ADCs
 - 2.2.1 Monoclonal Antibodies (mAbs)
 - 2.2.2 Linkers
 - 2.2.3 Payloads

3. ANTIBODY DRUG CONJUGATES - MECHANISM OF ACTION

- 3.1 Antigen - Antibody Interaction
- 3.2 Release of Payload
- 3.3 Mechanism of Cytotoxicity

4. NEED OF ANTIBODY DRUG CONJUGATES

5. ROLE OF ADCs IN CANCER MANAGEMENT

- 5.1 Breast Cancer
- 5.2 Leukemia
- 5.3 Lymphoma
- 5.4 Other Cancers

6. ANTIBODY DRUG CONJUGATE MARKET ANALYSIS

- 6.1 Overview
- 6.2 Current Market Scenario
- 6.3 ADCs Market Segmentation
 - 6.3.1 Regional Segmentation

6.3.2 Segmentation By Products

7. GLOBAL – CANCER ANTIBODY DRUG CONJUGATE MARKET INSIGHTS

7.1 US

7.2 Europe

7.2.1 Germany

7.2.2 Belgium

7.2.3 France

7.2.4 United Kingdom

7.3 Japan

7.4 China

7.5 India

7.6 South Korea

8. ANTIBODY DRUG CONJUGATES - AVAILABILITY, DOSAGE & PRICE ANALYSIS

8.1 Mylotarg (Gemtuzumab ozogamicin)

8.2 Adcetris (Brentuximab vedotin)

8.3 Kadcyla (Trastuzumab emtansine)

8.4 Besponsa (Inotuzumab ozogamicin)

8.5 Lumoxiti (Moxetumomab pasudotox)

8.6 Polivy (Polatuzumab vedotin)

8.7 Enhertu (Fam-Trastuzumab Deruxtecan-Nxki)

8.8 Padcev (Enfortumab Vedotin)

9. ANTIBODY DRUG CONJUGATES - SALES INSIGHT

9.1 Kadcyla

9.2 Adcetris

9.3 Polivy

10. ANTIBODY DRUG CONJUGATES - CLINICAL PIPELINE INSIGHT 2020 - 2026

10.1 By Phase

10.2 By Indication

10.3 By Company

10.4 By Patient Segment

10.5 By Country

10.6 By Mechanism of Action

11. GLOBAL CANCER DRUG CONJUGATES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

11.1 Research

11.2 Preclinical

11.3 Clinical

11.4 Phase-0

11.5 Phase-I

11.6 Phase-I/II

11.7 Phase-II

11.8 Phase-II/III

11.9 Phase-III

11.10 Preregistration

11.11 Registered

12. MARKETED CANCER DRUG CONJUGATES CLINICAL INSIGHT

12.1 Adcetris

12.2 Mylotarg

12.3 Junovan/Mepact

12.4 Kadcyła

12.5 Besponsa

12.6 Zevalin/ Zevamab

12.7 LUMOXITI

12.8 OncoScint CR/OV

12.9 Enhertu

13. GLOBAL CANCER AN ANTIBODY DRUG CONJUGATES MARKET DYNAMICS

13.1 Favorable Parameters

13.2 Challenges for Antibody Drug Conjugates Market

14. ANTIBODY DRUG CONJUGATES MARKET - FUTURE OUTLOOK

15. COMPETITIVE LANDSCAPE

- 15.1 AstraZeneca plc
- 15.2 Genentech
- 15.3 Roche
- 15.4 Takeda Pharmaceuticals
- 15.5 Pfizer
- 15.6 Oxford BioTherapeutics
- 15.7 Heidelberg Pharma
- 15.8 Synthon
- 15.9 Mersana Therapeutics
- 15.10 Progenics Pharmaceuticals
- 15.11 Astellas Pharma
- 15.12 Bristol Mayer Squibb
- 15.13 Seattle Genetics
- 15.14 Immunogen
- 15.15 Celldex Therapeutics

List Of Figures

LIST OF FIGURES

- Figure 1-1: Historical Development of Antibody-Drug Conjugate
- Figure 1-2: Approval History of Commercially Available Antibody-Drug Conjugates
- Figure 2-1: Classification of Antibody-Drug Conjugates
- Figure 2-2: Components of Antibody-Drug Conjugates
- Figure 2-3: Antigen Expression Analyzing Techniques used in Development of ADCs
- Figure 2-4: Isotypes of Monoclonal Antibodies used in ADC Development
- Figure 2-5: Classification of Linkers
- Figure 2-6: Types of Cleavable Linkers
- Figure 2-7: Non-Cleavable Linker Used in ADCs Development
- Figure 2-8: Cytotoxic Drugs Used in Antibody Drug Conjugates
- Figure 3-1: General Mechanism of Antibody Drug Conjugates against Cancer
- Figure 3-2: ADCs - Antigen-Antibody Interaction in Normal & Cancerous Cells
- Figure 3-3: Releasing Mechanism of Payloads
- Figure 3-4: Mechanism of Cytotoxicity via Alkylating Agents
- Figure 3-5: Mechanism of Toxicity via Tubulin Inhibitors
- Figure 4 1: Therapeutic Index – Antibody Drug Conjugate vs. Cytotoxic Drug
- Figure 6-1: Global - Number of Breast Cancer Cases & HER2+ Breast Cancer Cases (Million), 2018
- Figure 6-2: Global - Number of HER2+ Breast Cancer Cases vs. Other Breast Cancer (%), 2018
- Figure 6-3: Survival Rate at Different Stages of Breast Cancer (%)
- Figure 6-4: Global – Newly Diagnosed ALL Cases & Deaths, 2019
- Figure 6-5: Global – Newly Diagnosed AML Cases & Deaths, 2019
- Figure 6-6: Global – Newly Diagnosed Non-Hodgkin Lymphoma Cases & Deaths, 2019
- Figure 6-7: Global – Newly Diagnosed AML Cases & Deaths, 2019
- Figure 6-8: Global – Cancer Drug Market – Total vs. ADCs (US\$ Billion), 2019
- Figure 6-9: Global – Cancer Drug Market – ADCs vs. Others (US\$ Billion), 2019
- Figure 6-10: Global – Antibody Drug Conjugates Market Size (US\$ Billion), 2018 & 2019
- Figure 6-11: Global – Antibody Drug Conjugates Market Opportunity (US\$ Billion), 2019 - 2026
- Figure 6-12: Global – Antibody Drug Conjugate Regional Market Share (%), 2019
- Figure 6-13: Global – Antibody Drug Conjugate Market Size – Total vs. Kadcyla (US\$ Billion), 2019
- Figure 6-14: Global – Antibody Drug Conjugate Market Share (%) – Kadcyla vs. Others, 2019

Figure 6-15: Global – Antibody Drug Conjugate Market Share (%) – Adcetris vs. Others, 2019

Figure 6-16: Global – Antibody Drug Conjugate Market Segmentation by Product (%), 2019

Figure 7-1: US- Cancer Statistics (Million), 2018

Figure 7-2: US – Clinical Trial Status for Cancer Antibody Drug Conjugates, 2020

Figure 7-3: Europe – Cancer Statistics (Million), 2018

Figure 7-4: Germany – Cancer Statistics (Million), 2018

Figure 7-5: Belgium – Cancer Statistics, 2018

Figure 7-6: France – Cancer Statistics (Million), 2018

Figure 7-7: United Kingdom – Cancer Statistics (US\$ Million), 2018

Figure 7-8: Japan – Cancer Death Statistics (%), 2018

Figure 7-9: Japan – Clinical Trial Status, 2020

Figure 7-10: Japan – Amount Paid by Company vs. Insured (%),

Figure 7-11: China – Cancer Statistics (Million), 2018

Figure 7-12: China – Clinical Trials for Cancer Antibody Drug Conjugate Drugs, 2020

Figure 7-13: China – Reimbursement Status Company vs. Insured (%), 2020

Figure 7-14: India – Cancer Statistics (Million), 2018

Figure 7-15: India – Research & Development Spending by Pharmaceutical Companies (US\$ Million), 2018

Figure 7-16: South Korea – Cancer Statistics (Million), 2018

Figure 7-17: South Korea – Clinical Trial Status, 2018

Figure 8-1: Commercially Available Antibody Drug Conjugates

Figure 8-2: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year

Figure 8-3: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML

Figure 8-4: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US\$), December'2019

Figure 8-5: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML, December'2019

Figure 8-6: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days), December'2019

Figure 8-7: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m²), December'2019

Figure 8-8: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US\$), December'2019

Figure 8-9: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, December'2019

Figure 8-10: Adcetris – Patent Issue & Expiration Year

Figure 8-11: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks), December'2019

Figure 8-12: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US\$), December'2019

Figure 8-13: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks), December'2019

Figure 8-14: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US\$), December'2019

Figure 8-15: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US\$), December'2019

Figure 8-16: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks), December'2019

Figure 8-17: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US\$), December'2019

Figure 8-18: Kadcyla – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer

Figure 8-19: Kadcyla – Price for Single Unit of 100mg & 150mg Intravenous Powder for Injection (US\$), December'2019

Figure 8-20: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks), December'2019

Figure 8-21: Kadcyla – Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US\$), December'2019

Figure 8-22: Kadcyla – Recommended Dose After 1st & 2nd Dose Reduction (mg/m²), December'2019

Figure 8-23: Besponsa – Orphan Market Exclusivity Issue & Expiration Year

Figure 8-24: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days), December'2019

Figure 8-25; Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m²), December'2019

Figure 8-26: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US\$), December'2019

Figure 8-27: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US\$), December'2019

Figure 8-28: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US\$), December'2019

Figure 8-29: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks), December'2019

Figure 8-30: Besponsa – Full Treatment Cost of ALL Patients with & Without Complete Remission after HSCT (US\$), December'2019

Figure 8-31: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration

Figure 8-32: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks), December'2019

Figure 8-33: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US\$), 2019

Figure 8-34: Polivy – Patent Issue & Expiration Year

Figure 8-35: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks), December'2019

Figure 8-36: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US\$), 2019

Figure 8-37: Bendamustine – Price for Single Unit & 4ml of 25mg/ml Bendamustine Intravenous Solution for Injection (US\$), December'2019

Figure 8-38: Rituximab – Price for 1ml & 10ml of 10mg/ml Rituximab Intravenous Solution for Injection (US\$), December'2019

Figure 8-39: Enhertu – FDA Priority Review & Approval Year

Figure 8-40: Enhertu – Disease Control, Tumor Shrinkage & Disease Elimination Rate (%)

Figure 8-41: Enhertu – Average Cost of Single Treatment Cycle & Annual Treatment Cost of Breast Cancer (US\$), March'2020

Figure 8-42: Enhertu – Recommended Dose & Dose after Reduction (mg/Kg), March'2020

Figure 8-43: Enhertu – Estimated Sales Value (US\$ Million), 2020 & 2026

Figure 8-44: Padcev – Price for 20mg & 30mg Intravenous Powder for Injection (US\$), March'2020

Figure 8-45: Padcev – Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US\$), March'2020

Figure 9-1: Kadcyla – Global Annual Sales Value (US\$ Million), 2016 - 2019

Figure 9-2: Kadcyla – Global Sales Value by Quarter (US\$ Billion), 2018

Figure 9-3: Kadcyla – Regional Sales Value (US\$ Million), 2018

Figure 9-4: Kadcyla – Share of Sales Value by Region (%), 2018

Figure 9-5: Kadcyla – Sales Value by Region (US\$/CHF Million), 2019

Figure 9-6: Kadcyla – Share of Sales Value by Region (%), 2019

Figure 9-7: Kadcyla – Global Sales Value of Q1 (US\$ Million), 2016 - 2019

Figure 9-8: Kadcyla – Quarterly Sales Value (US\$ Million), 2019

Figure 9-9: North America - Adcetris Sales Value (US\$ Million), 2016 – 2019

Figure 9-10: North America - Adcetris Half Year Sales Value (US\$ Million), 2018 & 2019

Figure 9-11: North America – Adcetris Quarterly Sales Value (US\$ Million), 2019

Figure 9-12: North America – Adcetris Sales Value by Quarters (US\$ Million), 2018

Figure 9-13: Polivy – Quarterly Sales Value (US\$/CHF Million), Q3 & Q4, 2019

Figure 10-1: Global – Antibody Drug Conjugate Clinical Pipeline by Phase (Numbers), 2020 till 2026

Figure 10-2: Global - Antibody Drug Conjugate Clinical Pipeline by Phase (%),2020 till 2026

Figure 10-3: Global – Antibody Drug Conjugate Clinical Pipeline by Indication, 2020 till 2026

Figure 10-4: Global – Antibody Drug Conjugate Clinical Pipeline by Company, 2020 till 2026

Figure 10-5: Global – Antibody Drug Conjugate Clinical Pipeline by Patient Segment, 2020 till 2026

Figure 10-6: Global – Antibody Drug Conjugate Clinical Pipeline by Country, 2020 till 2026

Figure 10-7: Global – Antibody Drug Conjugate Clinical Pipeline by Company, 2020 till 2026

Figure 13-1: Antibody Drug Conjugates Market Drivers

Figure 13-2: Challenges for Antibody Drug Conjugates Market

I would like to order

Product name: Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/G055DA2F285AEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G055DA2F285AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

